{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T15:03:08Z","timestamp":1768402988307,"version":"3.49.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T00:00:00Z","timestamp":1554940800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12890-019-0841-7","type":"journal-article","created":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T06:13:33Z","timestamp":1554963213000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5203-7911","authenticated-orcid":false,"given":"Satoshi","family":"Ikeda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akimasa","family":"Sekine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohisa","family":"Baba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuma","family":"Katano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erina","family":"Tabata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryota","family":"Shintani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinko","family":"Sadoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Yamakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuneyuki","family":"Oda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Okuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideya","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae","family":"Iwasawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamiko","family":"Takemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,11]]},"reference":[{"key":"841_CR1","doi-asserted-by":"publisher","first-page":"17074","DOI":"10.1038\/nrdp.2017.74","volume":"3","author":"FJ Martinez","year":"2017","unstructured":"Martinez FJ, Collard HR, Pardo A, Raghu G, Richeldi L, Selman M, Swigris JJ, Taniguchi H, Wells AU. Idiopathic pulmonary fibrosis. Nat Rev Dis Primers. 2017;3:17074.","journal-title":"Nat Rev Dis Primers"},{"key":"841_CR2","doi-asserted-by":"publisher","first-page":"170071","DOI":"10.1183\/16000617.0071-2017","volume":"26","author":"G Raghu","year":"2017","unstructured":"Raghu G. Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential. Eur Respir Rev. 2017;26:170071.","journal-title":"Eur Respir Rev"},{"key":"841_CR3","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","volume":"370","author":"TE King Jr","year":"2014","unstructured":"King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW, ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083\u201392.","journal-title":"N Engl J Med"},{"key":"841_CR4","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR, INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071\u201382.","journal-title":"N Engl J Med"},{"key":"841_CR5","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s12931-015-0276-5","volume":"16","author":"T Corte","year":"2015","unstructured":"Corte T, Bonella F, Crestani B, Demedts MG, Richeldi L, Coeck C, Pelling K, Quaresma M, Lasky JA. Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis. Respir Res. 2015;16:116.","journal-title":"Respir Res"},{"key":"841_CR6","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1164\/rccm.201506-1063ST","volume":"192","author":"G Raghu","year":"2015","unstructured":"Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J, Brozek JL, Collard HR, Cunningham W, Homma S, Johkoh T, Martinez FJ, Myers J, Protzko SL, Richeldi L, Rind D, Selman M, Theodore A, Wells AU, Hoogsteden H, Sch\u00fcnemann HJ, American Thoracic Society; European Respiratory society; Japanese Respiratory Society; Latin American Thoracic Association. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;192:e3\u2013e19.","journal-title":"Am J Respir Crit Care Med"},{"key":"841_CR7","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1136\/thoraxjnl-2014-206598","volume":"70","author":"S Suissa","year":"2015","unstructured":"Suissa S, Ernst P. The INPULSIS enigma: exacerbations in idiopathic pulmonary fibrosis. Thorax. 2015;70:508\u201310.","journal-title":"Thorax"},{"key":"841_CR8","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.pupt.2016.07.009","volume":"40","author":"P Rogliani","year":"2016","unstructured":"Rogliani P, Calzetta L, Cavalli F, Matera MG, Cazzola M. Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Pulm Pharmacol Ther. 2016;40:95\u2013103.","journal-title":"Pulm Pharmacol Ther"},{"issue":"Suppl 60","key":"841_CR9","first-page":"[Abstract ID -","volume":"48","author":"B Crestani","year":"2016","unstructured":"Crestani B, Quaresma M, Kaye M, Stansen W, Stowasser S, Kreuter M. Long-term treatment with nintedanib in patients with IPF: An update from INPULSIS\u00ae-ON [abstract]. Eur Respir J. 2016;48(Suppl 60):[Abstract ID - OA4960].","journal-title":"Eur Respir J"},{"key":"841_CR10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S2213-2600(16)30326-5","volume":"5","author":"SD Nathan","year":"2017","unstructured":"Nathan SD, Albera C, Bradford WZ, Costabel U, Glaspole I, Glassberg MK, Kardatzke DR, Daigl M, Kirchgaessler KU, Lancaster LH, Lederer DJ, Pereira CA, Swigris JJ, Valeyre D, Noble PW. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. Lancet Respir Med. 2017;5:33\u201341.","journal-title":"Lancet Respir Med"},{"key":"841_CR11","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1183\/13993003.00584-2015","volume":"46","author":"K Milger","year":"2015","unstructured":"Milger K, Kneidinger N, Neurohr C, Reichenberger F, Behr J. Switching to nintedanib after discontinuation of pirfenidone due to adverse events in IPF. Eur Respir J. 2015;46:1217\u201321.","journal-title":"Eur Respir J"},{"key":"841_CR12","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","volume":"183","author":"G Raghu","year":"2011","unstructured":"Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, M\u00fcller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Sch\u00fcnemann HJ, ATS\/ERS\/JRS\/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788\u2013824.","journal-title":"Am J Respir Crit Care Med"},{"key":"841_CR13","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) ver.4.0. \n                    http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_40\n                    \n                  . Accessed 17 Dec 2016."},{"key":"841_CR14","unstructured":"Boehringer Ingelheim [Internet], Japan: [Guide for appropriate use of nintedanib (Ofev\u00ae)]. \n                    https:\/\/www.boehringerplus.jp\/sites\/all\/themes\/jp\/nbi\/pdf\/product-page\/basic-documents\/products\/attach\/pdf\/ofe_cap_guide.pdf\n                    \n                   (in Japanese). Accessed 17 Dec 2016."},{"key":"841_CR15","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"841_CR16","doi-asserted-by":"publisher","first-page":"10811","DOI":"10.1038\/s41598-017-11321-x","volume":"7","author":"S Ikeda","year":"2017","unstructured":"Ikeda S, Sekine A, Baba T, Yamanaka Y, Sadoyama S, Yamakawa H, Oda T, Okuda R, Kitamura H, Okudela K, Iwasawa T, Ohashi K, Takemura T, Ogura T. Low body surface area predicts hepatotoxicity of nintedanib in patients with idiopathic pulmonary fibrosis. Sci Rep. 2017;7:10811.","journal-title":"Sci Rep"},{"key":"841_CR17","first-page":"136","volume":"10","author":"U Schmid","year":"2017","unstructured":"Schmid U, Doege C, Dallinger C, Freiwald M. Population pharmacokinetics of nintedanib in patients with idiopathic pulmonary fibrosis. Pulm Pharmacol Ther. 2017;10:136\u201343.","journal-title":"Pulm Pharmacol Ther"},{"issue":"4","key":"841_CR18","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1159\/000490355","volume":"96","author":"Y Nakatsuka","year":"2018","unstructured":"Nakatsuka Y, Handa T, Kokosi M, Tanizawa K, Puglisi S, Jacob J, Sokai A, Ikezoe K, Kanatani KT, Kubo T, Tomioka H, Taguchi Y, Nagai S, Chin K, Mishima M, Wells AU, Hirai T. The clinical significance of body weight loss in idiopathic pulmonary fibrosis patients. Respiration. 2018;96(4):338\u201347.","journal-title":"Respiration"},{"key":"841_CR19","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1111\/resp.12297","volume":"19","author":"D Valeyre","year":"2014","unstructured":"Valeyre D, Albera C, Bradford WZ, Costabel U, King TE Jr, Leff JA, Noble PW, Sahn SA, du Bois RM. Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. Respirology. 2014;19:740\u20137.","journal-title":"Respirology"},{"key":"841_CR20","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.resinv.2015.06.001","volume":"53","author":"T Ogura","year":"2015","unstructured":"Ogura T, Azuma A, Inoue Y, Taniguchi H, Chida K, Bando M, Niimi Y, Kakutani S, Suga M, Sugiyama Y, Kudoh S, Nukiwa T. All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis. Respir Investig. 2015;53:232\u201341.","journal-title":"Respir Investig"},{"key":"841_CR21","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1136\/thoraxjnl-2015-207011","volume":"71","author":"SD Nathan","year":"2016","unstructured":"Nathan SD, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Glasscock KF, King TE Jr, Lancaster L, Lederer DJ, Lin Z, Pereira CA, Swigris JJ, Valeyre D, Noble PW, Wells AU. Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. Thorax. 2016;71:429\u201335.","journal-title":"Thorax"},{"key":"841_CR22","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1183\/09031936.00198013","volume":"45","author":"T Ogura","year":"2015","unstructured":"Ogura T, Taniguchi H, Azuma A, Inoue Y, Kondoh Y, Hasegawa Y, Bando M, Abe S, Mochizuki Y, Chida K, Kl\u00fcglich M, Fujimoto T, Okazaki K, Tadayasu Y, Sakamoto W, Sugiyama Y. Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2015;45:1382\u201392.","journal-title":"Eur Respir J"},{"key":"841_CR23","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1164\/rccm.201706-1301OC","volume":"197","author":"C Vancheri","year":"2018","unstructured":"Vancheri C, Kreuter M, Richeldi L, Ryerson CJ, Valeyre D, Grutters JC, Wiebe S, Stansen W, Quaresma M, Stowasser S, Wuyts WA, INJOURNEY Trial Investigators. Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis: results of the INJOURNEY trial. Am J Respir Crit Care Med. 2018;197:356\u201363.","journal-title":"Am J Respir Crit Care Med"},{"key":"841_CR24","first-page":"[Abstract ID \u2013","volume":"195","author":"K Flaherty","year":"2017","unstructured":"Flaherty K, Sussman R, Pesci A, Nunes H, Acosta O, Petzinger U, Stauffer J, Gilberg F, Bengus M, Lancaster LH. Safety of the combined use of Pirfenidone and Nintedanib in patients with idiopathic pulmonary fibrosis (IPF): results from an interim analysis after 12 weeks [abstract]. Am J Respir Crit Care Med. 2017;195:[Abstract ID \u2013 A5398].","journal-title":"Am J Respir Crit Care Med"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-019-0841-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12890-019-0841-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-019-0841-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T23:08:06Z","timestamp":1586473686000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-019-0841-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,11]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["841"],"URL":"https:\/\/doi.org\/10.1186\/s12890-019-0841-7","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,11]]},"assertion":[{"value":"2 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Ethics Committee of the Kanagawa Cardiovascular and Respiratory Center approved the study protocol (approval date: January 16, 2018; approved number: KCRC-17-0040), and the need for patient consent was waived because this was a retrospective study and anonymity was secured.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"S Ikeda, A Sekine, T Baba, T Katano, E Tabata, R Shintani, S Sadoyama, H Yamakawa, T Oda, R Okuda, H Kitamura, T Iwasawa, and T Takemura declare that no potential conflicts of interest exist with any companies\/organizations whose products or services may be discussed in this article. T Ogura received an honorarium from Boehringer Ingelheim Co., Ltd. and Shionogi & Co., Ltd.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"78"}}